Phase 2 Rheumatoid Arthritis Trial, Recruiting NCT07048197 Sponsor: Novartis Pharmaceuticals Condition: Rheumatoid Arthritis
Back to Rheumatoid Arthritis

Phase 2 Rheumatoid Arthritis Trial, Recruiting

NCT07048197
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You must be willing and able to sign a consent form before taking part in the study
  • You must be between 18 and 75 years old at the time of your initial screening appointment
  • (For Rheumatoid Arthritis patients) You have been diagnosed with rheumatoid arthritis, your condition is currently active, and previous standard treatments have not worked well enough for you
  • (For Sjögren's Disease patients) You have been diagnosed with Sjögren's disease and your condition is currently active

Who may not be able to join:

  • Your Body Mass Index (BMI — a measure of weight relative to height) is very low (17 or under) or very high (40 or over)
  • You currently have a significant, ongoing, or recurring infection
  • You are a sexually active male who is unwilling to use a condom during sex from the time you enroll in the study
  • You are a woman who could become pregnant and are not using a highly effective form of contraception from the time of enrollment
  • You are pregnant, currently breastfeeding, or planning to become pregnant during the study
  • Your kidneys, liver, or other organs are not functioning well enough at the time of screening (confirm with trial site)
  • You have a history of certain blood cancers, any other cancer, or a history of cancer in the past
  • You have previously had a bone marrow, stem cell, or solid organ transplant
  • You have a psychiatric condition or disability that would make it difficult to follow the treatment plan or give informed consent
  • There may be additional criteria not listed here that the trial team will check

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 15 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: +41613241111

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Registry
ClinicalTrials.gov
Start date
20 June 2025
Est. completion
1 November 2028

Where this trial is recruiting

🇫🇷 France 🇩🇪 Germany 🇸🇬 Singapore 🇪🇸 Spain

Primary endpoints

Number of Participants with Adverse Events as a Measure of Safety and Tolerability

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 15 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov